[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f2Dz72PFj80P8LnNVjrHrjcE1UHv8jdzt5-mik3QpR0Y":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":64,"rows":71},"Goethe University",[4],97,false,19,5,46736,12,70,[14,17,20,23,25,27,29,31],{"name":15,"count":16},"Adult Acute Lymphocytic Leukemia",7,{"name":18,"count":19},"Acute Lymphoblastic Leukemia",3,{"name":21,"count":22},"Humerus Fracture Displaced Proximal",2,{"name":24,"count":22},"Fascia",{"name":26,"count":22},"Depression",{"name":28,"count":22},"Anxiety Disorder",{"name":30,"count":22},"Platelet Function",{"name":32,"count":22},"Subarachnoid Hemorrhage",[34,39,44,49,54,59],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05281406","Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)","2025-11","Osimertinib",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT05182385","Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed\u002FRefractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed\u002FRefractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)","2026-04-30","Blinatumomab",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT04230759","Radiochemotherapy +\u002F- Durvalumab for Locally-advanced Anal Carcinoma. a Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group","2026-12-31","Chemotherapy",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT07488910","Dynamic Networks in Depression Treatment: Mechanisms of Change in Pharmacological, Psychological and Combined Treatment of Depression","2028-01","Psychopharmacological treatment",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06648889","Isatuximab in Adult Patients With Cytologic or Molecular Relapsed\u002FRefractory CD38 Positive T-cell Acute Lymphoblastic Leukemia","2028-02","Isatuximab",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT06061094","Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT","2029-07-01","Imatinib",[65,66,67,68,69,70],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[72,96,150,194,220,238,256,274,300,318,336,358,376,460,498,536,570,604,640,670,700,730,756,782,808,834,860,882,904,926,948,979,1001,1031,1053,1075,1093,1111,1129,1147,1165,1183,1201,1219,1246,1264,1282,1308,1326,1352,1378,1396,1414,1432,1450,1475,1499,1517,1541,1567,1585,1610,1628],{"intervention":53,"totalTrials":73,"cells":74},1,{"EARLY_PHASE1":75,"PHASE1":78,"PHASE2":80,"PHASE3":82,"PHASE4":84,"NA":94},{"trials":76,"activeCount":77},[],0,{"trials":79,"activeCount":77},[],{"trials":81,"activeCount":77},[],{"trials":83,"activeCount":77},[],{"trials":85,"activeCount":73,"soonestReadout":52},[86],{"nctId":50,"briefTitle":51,"status":87,"phases":88,"primaryCompletion":52,"completion":52,"start":89,"enrollment":90,"conditions":91,"interventions":93},"NOT_YET_RECRUITING",[69],"2026-02",90,[92],"Depression - Major Depressive Disorder",[53],{"trials":95,"activeCount":77},[],{"intervention":43,"totalTrials":97,"cells":98},4,{"EARLY_PHASE1":99,"PHASE1":101,"PHASE2":103,"PHASE3":144,"PHASE4":146,"NA":148},{"trials":100,"activeCount":77},[],{"trials":102,"activeCount":77},[],{"trials":104,"activeCount":22,"soonestReadout":42},[105,114,125,136],{"nctId":60,"briefTitle":61,"status":106,"phases":107,"primaryCompletion":62,"completion":62,"start":108,"enrollment":109,"conditions":110,"interventions":112},"RECRUITING",[67],"2023-07-14",220,[111],"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",[63,113,43],"Ponatinib",{"nctId":115,"briefTitle":116,"status":117,"phases":118,"primaryCompletion":119,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":124},"NCT03480438","Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab","COMPLETED",[67],"2024-01-10","2018-06-01",52,[123],"B-Precursor ALL",[43],{"nctId":126,"briefTitle":127,"status":117,"phases":128,"primaryCompletion":129,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":135},"NCT03109093","Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia",[67],"2021-08-15","2023-03-10","2017-03-15",83,[134],"ALL, Recurrent, Adult",[43],{"nctId":40,"briefTitle":41,"status":137,"phases":138,"primaryCompletion":42,"completion":42,"start":139,"enrollment":140,"conditions":141,"interventions":142},"ACTIVE_NOT_RECRUITING",[66,67],"2021-12-15",30,[134],[43,143],"Venetoclax",{"trials":145,"activeCount":77},[],{"trials":147,"activeCount":77},[],{"trials":149,"activeCount":77},[],{"intervention":63,"totalTrials":22,"cells":151},{"EARLY_PHASE1":152,"PHASE1":154,"PHASE2":156,"PHASE3":162,"PHASE4":190,"NA":192},{"trials":153,"activeCount":77},[],{"trials":155,"activeCount":77},[],{"trials":157,"activeCount":73,"soonestReadout":62},[158],{"nctId":60,"briefTitle":61,"status":106,"phases":159,"primaryCompletion":62,"completion":62,"start":108,"enrollment":109,"conditions":160,"interventions":161},[67],[111],[63,113,43],{"trials":163,"activeCount":77},[164],{"nctId":165,"briefTitle":166,"status":117,"phases":167,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":173},"NCT02881086","Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment",[68],"2024-12","2016-08",1023,[18,172],"Lymphoblastic Lymphoma",[174,175,176,63,177,178,179,180,181,182,183,184,185,186,187,188,189],"Rituximab","Nelarabine","PEG-Asparaginase","Idarubicin","Dexamethasone","Cyclophosphamide","Fludarabine","Vincristine","Mercaptopurine","VP16","Daunorubicin","Methotrexate","Cytarabine","Vindesine","Adriamycin","Prednisolone",{"trials":191,"activeCount":77},[],{"trials":193,"activeCount":77},[],{"intervention":38,"totalTrials":73,"cells":195},{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":214,"PHASE4":216,"NA":218},{"trials":197,"activeCount":77},[],{"trials":199,"activeCount":77},[],{"trials":201,"activeCount":73,"soonestReadout":37},[202],{"nctId":35,"briefTitle":36,"status":106,"phases":203,"primaryCompletion":37,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":210},[67],"2026-11","2021-11-12",50,[208,209],"NSCLC Stage IIIB","NSCLC Stage IV",[38,211,212,213],"Pemetrexed","Cisplatin","Carboplatin",{"trials":215,"activeCount":77},[],{"trials":217,"activeCount":77},[],{"trials":219,"activeCount":77},[],{"intervention":211,"totalTrials":73,"cells":221},{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":232,"PHASE4":234,"NA":236},{"trials":223,"activeCount":77},[],{"trials":225,"activeCount":77},[],{"trials":227,"activeCount":73,"soonestReadout":37},[228],{"nctId":35,"briefTitle":36,"status":106,"phases":229,"primaryCompletion":37,"completion":204,"start":205,"enrollment":206,"conditions":230,"interventions":231},[67],[208,209],[38,211,212,213],{"trials":233,"activeCount":77},[],{"trials":235,"activeCount":77},[],{"trials":237,"activeCount":77},[],{"intervention":212,"totalTrials":73,"cells":239},{"EARLY_PHASE1":240,"PHASE1":242,"PHASE2":244,"PHASE3":250,"PHASE4":252,"NA":254},{"trials":241,"activeCount":77},[],{"trials":243,"activeCount":77},[],{"trials":245,"activeCount":73,"soonestReadout":37},[246],{"nctId":35,"briefTitle":36,"status":106,"phases":247,"primaryCompletion":37,"completion":204,"start":205,"enrollment":206,"conditions":248,"interventions":249},[67],[208,209],[38,211,212,213],{"trials":251,"activeCount":77},[],{"trials":253,"activeCount":77},[],{"trials":255,"activeCount":77},[],{"intervention":213,"totalTrials":73,"cells":257},{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":262,"PHASE3":268,"PHASE4":270,"NA":272},{"trials":259,"activeCount":77},[],{"trials":261,"activeCount":77},[],{"trials":263,"activeCount":73,"soonestReadout":37},[264],{"nctId":35,"briefTitle":36,"status":106,"phases":265,"primaryCompletion":37,"completion":204,"start":205,"enrollment":206,"conditions":266,"interventions":267},[67],[208,209],[38,211,212,213],{"trials":269,"activeCount":77},[],{"trials":271,"activeCount":77},[],{"trials":273,"activeCount":77},[],{"intervention":48,"totalTrials":73,"cells":275},{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":294,"PHASE4":296,"NA":298},{"trials":277,"activeCount":77},[],{"trials":279,"activeCount":77},[],{"trials":281,"activeCount":73,"soonestReadout":47},[282],{"nctId":45,"briefTitle":46,"status":137,"phases":283,"primaryCompletion":47,"completion":284,"start":285,"enrollment":286,"conditions":287,"interventions":292},[67],"2027-03-31","2020-01-07",180,[288,289,290,291],"Anal Cancer","Anal Carcinoma","Anal Cancer Stage III","Anal Cancer Stage II",[48,293],"Durvalumab",{"trials":295,"activeCount":77},[],{"trials":297,"activeCount":77},[],{"trials":299,"activeCount":77},[],{"intervention":293,"totalTrials":73,"cells":301},{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":312,"PHASE4":314,"NA":316},{"trials":303,"activeCount":77},[],{"trials":305,"activeCount":77},[],{"trials":307,"activeCount":73,"soonestReadout":47},[308],{"nctId":45,"briefTitle":46,"status":137,"phases":309,"primaryCompletion":47,"completion":284,"start":285,"enrollment":286,"conditions":310,"interventions":311},[67],[288,289,290,291],[48,293],{"trials":313,"activeCount":77},[],{"trials":315,"activeCount":77},[],{"trials":317,"activeCount":77},[],{"intervention":113,"totalTrials":73,"cells":319},{"EARLY_PHASE1":320,"PHASE1":322,"PHASE2":324,"PHASE3":330,"PHASE4":332,"NA":334},{"trials":321,"activeCount":77},[],{"trials":323,"activeCount":77},[],{"trials":325,"activeCount":73,"soonestReadout":62},[326],{"nctId":60,"briefTitle":61,"status":106,"phases":327,"primaryCompletion":62,"completion":62,"start":108,"enrollment":109,"conditions":328,"interventions":329},[67],[111],[63,113,43],{"trials":331,"activeCount":77},[],{"trials":333,"activeCount":77},[],{"trials":335,"activeCount":77},[],{"intervention":58,"totalTrials":73,"cells":337},{"EARLY_PHASE1":338,"PHASE1":340,"PHASE2":342,"PHASE3":352,"PHASE4":354,"NA":356},{"trials":339,"activeCount":77},[],{"trials":341,"activeCount":77},[],{"trials":343,"activeCount":73,"soonestReadout":57},[344],{"nctId":55,"briefTitle":56,"status":106,"phases":345,"primaryCompletion":57,"completion":346,"start":347,"enrollment":348,"conditions":349,"interventions":351},[67],"2028-08","2024-10-22",40,[350],"T-ALL",[58,58],{"trials":353,"activeCount":77},[],{"trials":355,"activeCount":77},[],{"trials":357,"activeCount":77},[],{"intervention":143,"totalTrials":73,"cells":359},{"EARLY_PHASE1":360,"PHASE1":362,"PHASE2":364,"PHASE3":370,"PHASE4":372,"NA":374},{"trials":361,"activeCount":77},[],{"trials":363,"activeCount":77},[],{"trials":365,"activeCount":73,"soonestReadout":42},[366],{"nctId":40,"briefTitle":41,"status":137,"phases":367,"primaryCompletion":42,"completion":42,"start":139,"enrollment":140,"conditions":368,"interventions":369},[66,67],[134],[43,143],{"trials":371,"activeCount":77},[],{"trials":373,"activeCount":77},[],{"trials":375,"activeCount":77},[],{"intervention":179,"totalTrials":377,"cells":378},6,{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":385,"PHASE4":391,"NA":458},{"trials":380,"activeCount":77},[],{"trials":382,"activeCount":77},[],{"trials":384,"activeCount":77},[],{"trials":386,"activeCount":77},[387],{"nctId":165,"briefTitle":166,"status":117,"phases":388,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":389,"interventions":390},[68],[18,172],[174,175,176,63,177,178,179,180,181,182,183,184,185,186,187,188,189],{"trials":392,"activeCount":77},[393,411,424,437,450],{"nctId":394,"briefTitle":395,"status":117,"phases":396,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":401,"interventions":402},"NCT00199069","German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05\u002F93)",[69],"1999-01","2001-05","1993-04",720,[15],[403,181,404,179,405,186,406,185,407,408,409,410],"Asparaginase","Daunorubicin, Adriamycin","Ifosfamide","Mitoxantrone","6-Mercaptopurine","6-Thioguanine","VM26","Dexamethasone \u002F Prednisolone",{"nctId":412,"briefTitle":413,"status":117,"phases":414,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":419,"interventions":420},"NCT00198978","German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",[69],"2011-06","2014-06","2003-01",377,[15],[179,410,186,177,421,182,185,174,422,181,423,403],"Granulocyte-Colony-Stimulating Factor","HDARAC","Depocyte",{"nctId":425,"briefTitle":426,"status":117,"phases":427,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":432,"interventions":433},"NCT00199056","German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06\u002F99)",[69],"2003-11","2005-12","1999-10",225,[15],[410,179,185,434,184,403,435,186,407,183,188,436,409,177,180,405],"Vincristine \u002F Vindesine","G-CSF","Thioguanine",{"nctId":438,"briefTitle":439,"status":117,"phases":440,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":445,"interventions":446},"NCT00198991","German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07\u002F2003)",[69],"2011-06-30","2013-06-30","2003-04",1883,[15],[179,178,181,184,403,185,186,182,435,187,447,189,188,436,448,177,180,449],"Etoposide","Teniposide","Cladribine",{"nctId":451,"briefTitle":452,"status":117,"phases":453,"primaryCompletion":454,"completion":454,"start":455,"enrollment":348,"conditions":456,"interventions":457},"NCT00199095","Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia",[69],"2003-06","1997-02",[15],[188,179,186,178,177,405,185,182,409,181],{"trials":459,"activeCount":77},[],{"intervention":185,"totalTrials":377,"cells":461},{"EARLY_PHASE1":462,"PHASE1":464,"PHASE2":466,"PHASE3":468,"PHASE4":474,"NA":496},{"trials":463,"activeCount":77},[],{"trials":465,"activeCount":77},[],{"trials":467,"activeCount":77},[],{"trials":469,"activeCount":77},[470],{"nctId":165,"briefTitle":166,"status":117,"phases":471,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":472,"interventions":473},[68],[18,172],[174,175,176,63,177,178,179,180,181,182,183,184,185,186,187,188,189],{"trials":475,"activeCount":77},[476,480,484,488,492],{"nctId":394,"briefTitle":395,"status":117,"phases":477,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":478,"interventions":479},[69],[15],[403,181,404,179,405,186,406,185,407,408,409,410],{"nctId":412,"briefTitle":413,"status":117,"phases":481,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":482,"interventions":483},[69],[15],[179,410,186,177,421,182,185,174,422,181,423,403],{"nctId":425,"briefTitle":426,"status":117,"phases":485,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":486,"interventions":487},[69],[15],[410,179,185,434,184,403,435,186,407,183,188,436,409,177,180,405],{"nctId":438,"briefTitle":439,"status":117,"phases":489,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":490,"interventions":491},[69],[15],[179,178,181,184,403,185,186,182,435,187,447,189,188,436,448,177,180,449],{"nctId":451,"briefTitle":452,"status":117,"phases":493,"primaryCompletion":454,"completion":454,"start":455,"enrollment":348,"conditions":494,"interventions":495},[69],[15],[188,179,186,178,177,405,185,182,409,181],{"trials":497,"activeCount":77},[],{"intervention":186,"totalTrials":377,"cells":499},{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":504,"PHASE3":506,"PHASE4":512,"NA":534},{"trials":501,"activeCount":77},[],{"trials":503,"activeCount":77},[],{"trials":505,"activeCount":77},[],{"trials":507,"activeCount":77},[508],{"nctId":165,"briefTitle":166,"status":117,"phases":509,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":510,"interventions":511},[68],[18,172],[174,175,176,63,177,178,179,180,181,182,183,184,185,186,187,188,189],{"trials":513,"activeCount":77},[514,518,522,526,530],{"nctId":394,"briefTitle":395,"status":117,"phases":515,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":516,"interventions":517},[69],[15],[403,181,404,179,405,186,406,185,407,408,409,410],{"nctId":412,"briefTitle":413,"status":117,"phases":519,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":520,"interventions":521},[69],[15],[179,410,186,177,421,182,185,174,422,181,423,403],{"nctId":425,"briefTitle":426,"status":117,"phases":523,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":524,"interventions":525},[69],[15],[410,179,185,434,184,403,435,186,407,183,188,436,409,177,180,405],{"nctId":438,"briefTitle":439,"status":117,"phases":527,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":528,"interventions":529},[69],[15],[179,178,181,184,403,185,186,182,435,187,447,189,188,436,448,177,180,449],{"nctId":451,"briefTitle":452,"status":117,"phases":531,"primaryCompletion":454,"completion":454,"start":455,"enrollment":348,"conditions":532,"interventions":533},[69],[15],[188,179,186,178,177,405,185,182,409,181],{"trials":535,"activeCount":77},[],{"intervention":177,"totalTrials":9,"cells":537},{"EARLY_PHASE1":538,"PHASE1":540,"PHASE2":542,"PHASE3":544,"PHASE4":550,"NA":568},{"trials":539,"activeCount":77},[],{"trials":541,"activeCount":77},[],{"trials":543,"activeCount":77},[],{"trials":545,"activeCount":77},[546],{"nctId":165,"briefTitle":166,"status":117,"phases":547,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":548,"interventions":549},[68],[18,172],[174,175,176,63,177,178,179,180,181,182,183,184,185,186,187,188,189],{"trials":551,"activeCount":77},[552,556,560,564],{"nctId":412,"briefTitle":413,"status":117,"phases":553,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":554,"interventions":555},[69],[15],[179,410,186,177,421,182,185,174,422,181,423,403],{"nctId":425,"briefTitle":426,"status":117,"phases":557,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":558,"interventions":559},[69],[15],[410,179,185,434,184,403,435,186,407,183,188,436,409,177,180,405],{"nctId":438,"briefTitle":439,"status":117,"phases":561,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":562,"interventions":563},[69],[15],[179,178,181,184,403,185,186,182,435,187,447,189,188,436,448,177,180,449],{"nctId":451,"briefTitle":452,"status":117,"phases":565,"primaryCompletion":454,"completion":454,"start":455,"enrollment":348,"conditions":566,"interventions":567},[69],[15],[188,179,186,178,177,405,185,182,409,181],{"trials":569,"activeCount":77},[],{"intervention":181,"totalTrials":9,"cells":571},{"EARLY_PHASE1":572,"PHASE1":574,"PHASE2":576,"PHASE3":578,"PHASE4":584,"NA":602},{"trials":573,"activeCount":77},[],{"trials":575,"activeCount":77},[],{"trials":577,"activeCount":77},[],{"trials":579,"activeCount":77},[580],{"nctId":165,"briefTitle":166,"status":117,"phases":581,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":582,"interventions":583},[68],[18,172],[174,175,176,63,177,178,179,180,181,182,183,184,185,186,187,188,189],{"trials":585,"activeCount":77},[586,590,594,598],{"nctId":394,"briefTitle":395,"status":117,"phases":587,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":588,"interventions":589},[69],[15],[403,181,404,179,405,186,406,185,407,408,409,410],{"nctId":412,"briefTitle":413,"status":117,"phases":591,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":592,"interventions":593},[69],[15],[179,410,186,177,421,182,185,174,422,181,423,403],{"nctId":438,"briefTitle":439,"status":117,"phases":595,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":596,"interventions":597},[69],[15],[179,178,181,184,403,185,186,182,435,187,447,189,188,436,448,177,180,449],{"nctId":451,"briefTitle":452,"status":117,"phases":599,"primaryCompletion":454,"completion":454,"start":455,"enrollment":348,"conditions":600,"interventions":601},[69],[15],[188,179,186,178,177,405,185,182,409,181],{"trials":603,"activeCount":77},[],{"intervention":178,"totalTrials":97,"cells":605},{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":610,"PHASE3":612,"PHASE4":628,"NA":638},{"trials":607,"activeCount":77},[],{"trials":609,"activeCount":77},[],{"trials":611,"activeCount":77},[],{"trials":613,"activeCount":77},[614,618],{"nctId":165,"briefTitle":166,"status":117,"phases":615,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":616,"interventions":617},[68],[18,172],[174,175,176,63,177,178,179,180,181,182,183,184,185,186,187,188,189],{"nctId":619,"briefTitle":620,"status":117,"phases":621,"primaryCompletion":622,"completion":622,"start":623,"enrollment":624,"conditions":625,"interventions":626},"NCT00199108","Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt",[67,68],"2008-06","2004-04",20,[15],[627,178],"Depocyt",{"trials":629,"activeCount":77},[630,634],{"nctId":438,"briefTitle":439,"status":117,"phases":631,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":632,"interventions":633},[69],[15],[179,178,181,184,403,185,186,182,435,187,447,189,188,436,448,177,180,449],{"nctId":451,"briefTitle":452,"status":117,"phases":635,"primaryCompletion":454,"completion":454,"start":455,"enrollment":348,"conditions":636,"interventions":637},[69],[15],[188,179,186,178,177,405,185,182,409,181],{"trials":639,"activeCount":77},[],{"intervention":182,"totalTrials":97,"cells":641},{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":654,"NA":668},{"trials":643,"activeCount":77},[],{"trials":645,"activeCount":77},[],{"trials":647,"activeCount":77},[],{"trials":649,"activeCount":77},[650],{"nctId":165,"briefTitle":166,"status":117,"phases":651,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":652,"interventions":653},[68],[18,172],[174,175,176,63,177,178,179,180,181,182,183,184,185,186,187,188,189],{"trials":655,"activeCount":77},[656,660,664],{"nctId":412,"briefTitle":413,"status":117,"phases":657,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":658,"interventions":659},[69],[15],[179,410,186,177,421,182,185,174,422,181,423,403],{"nctId":438,"briefTitle":439,"status":117,"phases":661,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":662,"interventions":663},[69],[15],[179,178,181,184,403,185,186,182,435,187,447,189,188,436,448,177,180,449],{"nctId":451,"briefTitle":452,"status":117,"phases":665,"primaryCompletion":454,"completion":454,"start":455,"enrollment":348,"conditions":666,"interventions":667},[69],[15],[188,179,186,178,177,405,185,182,409,181],{"trials":669,"activeCount":77},[],{"intervention":188,"totalTrials":97,"cells":671},{"EARLY_PHASE1":672,"PHASE1":674,"PHASE2":676,"PHASE3":678,"PHASE4":684,"NA":698},{"trials":673,"activeCount":77},[],{"trials":675,"activeCount":77},[],{"trials":677,"activeCount":77},[],{"trials":679,"activeCount":77},[680],{"nctId":165,"briefTitle":166,"status":117,"phases":681,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":682,"interventions":683},[68],[18,172],[174,175,176,63,177,178,179,180,181,182,183,184,185,186,187,188,189],{"trials":685,"activeCount":77},[686,690,694],{"nctId":425,"briefTitle":426,"status":117,"phases":687,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":688,"interventions":689},[69],[15],[410,179,185,434,184,403,435,186,407,183,188,436,409,177,180,405],{"nctId":438,"briefTitle":439,"status":117,"phases":691,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":692,"interventions":693},[69],[15],[179,178,181,184,403,185,186,182,435,187,447,189,188,436,448,177,180,449],{"nctId":451,"briefTitle":452,"status":117,"phases":695,"primaryCompletion":454,"completion":454,"start":455,"enrollment":348,"conditions":696,"interventions":697},[69],[15],[188,179,186,178,177,405,185,182,409,181],{"trials":699,"activeCount":77},[],{"intervention":403,"totalTrials":97,"cells":701},{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":708,"PHASE4":710,"NA":728},{"trials":703,"activeCount":77},[],{"trials":705,"activeCount":77},[],{"trials":707,"activeCount":77},[],{"trials":709,"activeCount":77},[],{"trials":711,"activeCount":77},[712,716,720,724],{"nctId":394,"briefTitle":395,"status":117,"phases":713,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":714,"interventions":715},[69],[15],[403,181,404,179,405,186,406,185,407,408,409,410],{"nctId":412,"briefTitle":413,"status":117,"phases":717,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":718,"interventions":719},[69],[15],[179,410,186,177,421,182,185,174,422,181,423,403],{"nctId":425,"briefTitle":426,"status":117,"phases":721,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":722,"interventions":723},[69],[15],[410,179,185,434,184,403,435,186,407,183,188,436,409,177,180,405],{"nctId":438,"briefTitle":439,"status":117,"phases":725,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":726,"interventions":727},[69],[15],[179,178,181,184,403,185,186,182,435,187,447,189,188,436,448,177,180,449],{"trials":729,"activeCount":77},[],{"intervention":180,"totalTrials":19,"cells":731},{"EARLY_PHASE1":732,"PHASE1":734,"PHASE2":736,"PHASE3":738,"PHASE4":744,"NA":754},{"trials":733,"activeCount":77},[],{"trials":735,"activeCount":77},[],{"trials":737,"activeCount":77},[],{"trials":739,"activeCount":77},[740],{"nctId":165,"briefTitle":166,"status":117,"phases":741,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":742,"interventions":743},[68],[18,172],[174,175,176,63,177,178,179,180,181,182,183,184,185,186,187,188,189],{"trials":745,"activeCount":77},[746,750],{"nctId":425,"briefTitle":426,"status":117,"phases":747,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":748,"interventions":749},[69],[15],[410,179,185,434,184,403,435,186,407,183,188,436,409,177,180,405],{"nctId":438,"briefTitle":439,"status":117,"phases":751,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":752,"interventions":753},[69],[15],[179,178,181,184,403,185,186,182,435,187,447,189,188,436,448,177,180,449],{"trials":755,"activeCount":77},[],{"intervention":184,"totalTrials":19,"cells":757},{"EARLY_PHASE1":758,"PHASE1":760,"PHASE2":762,"PHASE3":764,"PHASE4":770,"NA":780},{"trials":759,"activeCount":77},[],{"trials":761,"activeCount":77},[],{"trials":763,"activeCount":77},[],{"trials":765,"activeCount":77},[766],{"nctId":165,"briefTitle":166,"status":117,"phases":767,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":768,"interventions":769},[68],[18,172],[174,175,176,63,177,178,179,180,181,182,183,184,185,186,187,188,189],{"trials":771,"activeCount":77},[772,776],{"nctId":425,"briefTitle":426,"status":117,"phases":773,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":774,"interventions":775},[69],[15],[410,179,185,434,184,403,435,186,407,183,188,436,409,177,180,405],{"nctId":438,"briefTitle":439,"status":117,"phases":777,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":778,"interventions":779},[69],[15],[179,178,181,184,403,185,186,182,435,187,447,189,188,436,448,177,180,449],{"trials":781,"activeCount":77},[],{"intervention":405,"totalTrials":19,"cells":783},{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":788,"PHASE3":790,"PHASE4":792,"NA":806},{"trials":785,"activeCount":77},[],{"trials":787,"activeCount":77},[],{"trials":789,"activeCount":77},[],{"trials":791,"activeCount":77},[],{"trials":793,"activeCount":77},[794,798,802],{"nctId":394,"briefTitle":395,"status":117,"phases":795,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":796,"interventions":797},[69],[15],[403,181,404,179,405,186,406,185,407,408,409,410],{"nctId":425,"briefTitle":426,"status":117,"phases":799,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":800,"interventions":801},[69],[15],[410,179,185,434,184,403,435,186,407,183,188,436,409,177,180,405],{"nctId":451,"briefTitle":452,"status":117,"phases":803,"primaryCompletion":454,"completion":454,"start":455,"enrollment":348,"conditions":804,"interventions":805},[69],[15],[188,179,186,178,177,405,185,182,409,181],{"trials":807,"activeCount":77},[],{"intervention":409,"totalTrials":19,"cells":809},{"EARLY_PHASE1":810,"PHASE1":812,"PHASE2":814,"PHASE3":816,"PHASE4":818,"NA":832},{"trials":811,"activeCount":77},[],{"trials":813,"activeCount":77},[],{"trials":815,"activeCount":77},[],{"trials":817,"activeCount":77},[],{"trials":819,"activeCount":77},[820,824,828],{"nctId":394,"briefTitle":395,"status":117,"phases":821,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":822,"interventions":823},[69],[15],[403,181,404,179,405,186,406,185,407,408,409,410],{"nctId":425,"briefTitle":426,"status":117,"phases":825,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":826,"interventions":827},[69],[15],[410,179,185,434,184,403,435,186,407,183,188,436,409,177,180,405],{"nctId":451,"briefTitle":452,"status":117,"phases":829,"primaryCompletion":454,"completion":454,"start":455,"enrollment":348,"conditions":830,"interventions":831},[69],[15],[188,179,186,178,177,405,185,182,409,181],{"trials":833,"activeCount":77},[],{"intervention":410,"totalTrials":19,"cells":835},{"EARLY_PHASE1":836,"PHASE1":838,"PHASE2":840,"PHASE3":842,"PHASE4":844,"NA":858},{"trials":837,"activeCount":77},[],{"trials":839,"activeCount":77},[],{"trials":841,"activeCount":77},[],{"trials":843,"activeCount":77},[],{"trials":845,"activeCount":77},[846,850,854],{"nctId":394,"briefTitle":395,"status":117,"phases":847,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":848,"interventions":849},[69],[15],[403,181,404,179,405,186,406,185,407,408,409,410],{"nctId":412,"briefTitle":413,"status":117,"phases":851,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":852,"interventions":853},[69],[15],[179,410,186,177,421,182,185,174,422,181,423,403],{"nctId":425,"briefTitle":426,"status":117,"phases":855,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":856,"interventions":857},[69],[15],[410,179,185,434,184,403,435,186,407,183,188,436,409,177,180,405],{"trials":859,"activeCount":77},[],{"intervention":174,"totalTrials":22,"cells":861},{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":868,"PHASE4":874,"NA":880},{"trials":863,"activeCount":77},[],{"trials":865,"activeCount":77},[],{"trials":867,"activeCount":77},[],{"trials":869,"activeCount":77},[870],{"nctId":165,"briefTitle":166,"status":117,"phases":871,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":872,"interventions":873},[68],[18,172],[174,175,176,63,177,178,179,180,181,182,183,184,185,186,187,188,189],{"trials":875,"activeCount":77},[876],{"nctId":412,"briefTitle":413,"status":117,"phases":877,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":878,"interventions":879},[69],[15],[179,410,186,177,421,182,185,174,422,181,423,403],{"trials":881,"activeCount":77},[],{"intervention":183,"totalTrials":22,"cells":883},{"EARLY_PHASE1":884,"PHASE1":886,"PHASE2":888,"PHASE3":890,"PHASE4":896,"NA":902},{"trials":885,"activeCount":77},[],{"trials":887,"activeCount":77},[],{"trials":889,"activeCount":77},[],{"trials":891,"activeCount":77},[892],{"nctId":165,"briefTitle":166,"status":117,"phases":893,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":894,"interventions":895},[68],[18,172],[174,175,176,63,177,178,179,180,181,182,183,184,185,186,187,188,189],{"trials":897,"activeCount":77},[898],{"nctId":425,"briefTitle":426,"status":117,"phases":899,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":900,"interventions":901},[69],[15],[410,179,185,434,184,403,435,186,407,183,188,436,409,177,180,405],{"trials":903,"activeCount":77},[],{"intervention":187,"totalTrials":22,"cells":905},{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":912,"PHASE4":918,"NA":924},{"trials":907,"activeCount":77},[],{"trials":909,"activeCount":77},[],{"trials":911,"activeCount":77},[],{"trials":913,"activeCount":77},[914],{"nctId":165,"briefTitle":166,"status":117,"phases":915,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":916,"interventions":917},[68],[18,172],[174,175,176,63,177,178,179,180,181,182,183,184,185,186,187,188,189],{"trials":919,"activeCount":77},[920],{"nctId":438,"briefTitle":439,"status":117,"phases":921,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":922,"interventions":923},[69],[15],[179,178,181,184,403,185,186,182,435,187,447,189,188,436,448,177,180,449],{"trials":925,"activeCount":77},[],{"intervention":189,"totalTrials":22,"cells":927},{"EARLY_PHASE1":928,"PHASE1":930,"PHASE2":932,"PHASE3":934,"PHASE4":940,"NA":946},{"trials":929,"activeCount":77},[],{"trials":931,"activeCount":77},[],{"trials":933,"activeCount":77},[],{"trials":935,"activeCount":77},[936],{"nctId":165,"briefTitle":166,"status":117,"phases":937,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":938,"interventions":939},[68],[18,172],[174,175,176,63,177,178,179,180,181,182,183,184,185,186,187,188,189],{"trials":941,"activeCount":77},[942],{"nctId":438,"briefTitle":439,"status":117,"phases":943,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":944,"interventions":945},[69],[15],[179,178,181,184,403,185,186,182,435,187,447,189,188,436,448,177,180,449],{"trials":947,"activeCount":77},[],{"intervention":406,"totalTrials":22,"cells":949},{"EARLY_PHASE1":950,"PHASE1":952,"PHASE2":954,"PHASE3":969,"PHASE4":971,"NA":977},{"trials":951,"activeCount":77},[],{"trials":953,"activeCount":77},[],{"trials":955,"activeCount":77},[956],{"nctId":957,"briefTitle":958,"status":117,"phases":959,"primaryCompletion":960,"completion":960,"start":961,"enrollment":962,"conditions":963,"interventions":965},"NCT00744081","Imatinib + MTC in Relapsed \u002F Refractory Acute Myeloid Leukemia (AML)",[67],"2010-12","2004-07",130,[964],"AML",[966,406,967,968],"Glivec","Topotecan","AraC",{"trials":970,"activeCount":77},[],{"trials":972,"activeCount":77},[973],{"nctId":394,"briefTitle":395,"status":117,"phases":974,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":975,"interventions":976},[69],[15],[403,181,404,179,405,186,406,185,407,408,409,410],{"trials":978,"activeCount":77},[],{"intervention":407,"totalTrials":22,"cells":980},{"EARLY_PHASE1":981,"PHASE1":983,"PHASE2":985,"PHASE3":987,"PHASE4":989,"NA":999},{"trials":982,"activeCount":77},[],{"trials":984,"activeCount":77},[],{"trials":986,"activeCount":77},[],{"trials":988,"activeCount":77},[],{"trials":990,"activeCount":77},[991,995],{"nctId":394,"briefTitle":395,"status":117,"phases":992,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":993,"interventions":994},[69],[15],[403,181,404,179,405,186,406,185,407,408,409,410],{"nctId":425,"briefTitle":426,"status":117,"phases":996,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":997,"interventions":998},[69],[15],[410,179,185,434,184,403,435,186,407,183,188,436,409,177,180,405],{"trials":1000,"activeCount":77},[],{"intervention":449,"totalTrials":22,"cells":1002},{"EARLY_PHASE1":1003,"PHASE1":1005,"PHASE2":1007,"PHASE3":1021,"PHASE4":1023,"NA":1029},{"trials":1004,"activeCount":77},[],{"trials":1006,"activeCount":77},[],{"trials":1008,"activeCount":77},[1009],{"nctId":1010,"briefTitle":1011,"status":117,"phases":1012,"primaryCompletion":1013,"completion":1013,"start":1014,"enrollment":1015,"conditions":1016,"interventions":1019},"NCT00199030","Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath",[67],"2008-04","2004-02",8,[1017,1018],"Adult Acute Lymphocytic Leukemia T-cell","Lymphoma, Lymphoblastic",[1020,449],"Alemtuzumab",{"trials":1022,"activeCount":77},[],{"trials":1024,"activeCount":77},[1025],{"nctId":438,"briefTitle":439,"status":117,"phases":1026,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":1027,"interventions":1028},[69],[15],[179,178,181,184,403,185,186,182,435,187,447,189,188,436,448,177,180,449],{"trials":1030,"activeCount":77},[],{"intervention":435,"totalTrials":22,"cells":1032},{"EARLY_PHASE1":1033,"PHASE1":1035,"PHASE2":1037,"PHASE3":1039,"PHASE4":1041,"NA":1051},{"trials":1034,"activeCount":77},[],{"trials":1036,"activeCount":77},[],{"trials":1038,"activeCount":77},[],{"trials":1040,"activeCount":77},[],{"trials":1042,"activeCount":77},[1043,1047],{"nctId":425,"briefTitle":426,"status":117,"phases":1044,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":1045,"interventions":1046},[69],[15],[410,179,185,434,184,403,435,186,407,183,188,436,409,177,180,405],{"nctId":438,"briefTitle":439,"status":117,"phases":1048,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":1049,"interventions":1050},[69],[15],[179,178,181,184,403,185,186,182,435,187,447,189,188,436,448,177,180,449],{"trials":1052,"activeCount":77},[],{"intervention":436,"totalTrials":22,"cells":1054},{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1059,"PHASE3":1061,"PHASE4":1063,"NA":1073},{"trials":1056,"activeCount":77},[],{"trials":1058,"activeCount":77},[],{"trials":1060,"activeCount":77},[],{"trials":1062,"activeCount":77},[],{"trials":1064,"activeCount":77},[1065,1069],{"nctId":425,"briefTitle":426,"status":117,"phases":1066,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":1067,"interventions":1068},[69],[15],[410,179,185,434,184,403,435,186,407,183,188,436,409,177,180,405],{"nctId":438,"briefTitle":439,"status":117,"phases":1070,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":1071,"interventions":1072},[69],[15],[179,178,181,184,403,185,186,182,435,187,447,189,188,436,448,177,180,449],{"trials":1074,"activeCount":77},[],{"intervention":404,"totalTrials":73,"cells":1076},{"EARLY_PHASE1":1077,"PHASE1":1079,"PHASE2":1081,"PHASE3":1083,"PHASE4":1085,"NA":1091},{"trials":1078,"activeCount":77},[],{"trials":1080,"activeCount":77},[],{"trials":1082,"activeCount":77},[],{"trials":1084,"activeCount":77},[],{"trials":1086,"activeCount":77},[1087],{"nctId":394,"briefTitle":395,"status":117,"phases":1088,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":1089,"interventions":1090},[69],[15],[403,181,404,179,405,186,406,185,407,408,409,410],{"trials":1092,"activeCount":77},[],{"intervention":408,"totalTrials":73,"cells":1094},{"EARLY_PHASE1":1095,"PHASE1":1097,"PHASE2":1099,"PHASE3":1101,"PHASE4":1103,"NA":1109},{"trials":1096,"activeCount":77},[],{"trials":1098,"activeCount":77},[],{"trials":1100,"activeCount":77},[],{"trials":1102,"activeCount":77},[],{"trials":1104,"activeCount":77},[1105],{"nctId":394,"briefTitle":395,"status":117,"phases":1106,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":1107,"interventions":1108},[69],[15],[403,181,404,179,405,186,406,185,407,408,409,410],{"trials":1110,"activeCount":77},[],{"intervention":421,"totalTrials":73,"cells":1112},{"EARLY_PHASE1":1113,"PHASE1":1115,"PHASE2":1117,"PHASE3":1119,"PHASE4":1121,"NA":1127},{"trials":1114,"activeCount":77},[],{"trials":1116,"activeCount":77},[],{"trials":1118,"activeCount":77},[],{"trials":1120,"activeCount":77},[],{"trials":1122,"activeCount":77},[1123],{"nctId":412,"briefTitle":413,"status":117,"phases":1124,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":1125,"interventions":1126},[69],[15],[179,410,186,177,421,182,185,174,422,181,423,403],{"trials":1128,"activeCount":77},[],{"intervention":422,"totalTrials":73,"cells":1130},{"EARLY_PHASE1":1131,"PHASE1":1133,"PHASE2":1135,"PHASE3":1137,"PHASE4":1139,"NA":1145},{"trials":1132,"activeCount":77},[],{"trials":1134,"activeCount":77},[],{"trials":1136,"activeCount":77},[],{"trials":1138,"activeCount":77},[],{"trials":1140,"activeCount":77},[1141],{"nctId":412,"briefTitle":413,"status":117,"phases":1142,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":1143,"interventions":1144},[69],[15],[179,410,186,177,421,182,185,174,422,181,423,403],{"trials":1146,"activeCount":77},[],{"intervention":423,"totalTrials":73,"cells":1148},{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1153,"PHASE3":1155,"PHASE4":1157,"NA":1163},{"trials":1150,"activeCount":77},[],{"trials":1152,"activeCount":77},[],{"trials":1154,"activeCount":77},[],{"trials":1156,"activeCount":77},[],{"trials":1158,"activeCount":77},[1159],{"nctId":412,"briefTitle":413,"status":117,"phases":1160,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":1161,"interventions":1162},[69],[15],[179,410,186,177,421,182,185,174,422,181,423,403],{"trials":1164,"activeCount":77},[],{"intervention":434,"totalTrials":73,"cells":1166},{"EARLY_PHASE1":1167,"PHASE1":1169,"PHASE2":1171,"PHASE3":1173,"PHASE4":1175,"NA":1181},{"trials":1168,"activeCount":77},[],{"trials":1170,"activeCount":77},[],{"trials":1172,"activeCount":77},[],{"trials":1174,"activeCount":77},[],{"trials":1176,"activeCount":77},[1177],{"nctId":425,"briefTitle":426,"status":117,"phases":1178,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":1179,"interventions":1180},[69],[15],[410,179,185,434,184,403,435,186,407,183,188,436,409,177,180,405],{"trials":1182,"activeCount":77},[],{"intervention":447,"totalTrials":73,"cells":1184},{"EARLY_PHASE1":1185,"PHASE1":1187,"PHASE2":1189,"PHASE3":1191,"PHASE4":1193,"NA":1199},{"trials":1186,"activeCount":77},[],{"trials":1188,"activeCount":77},[],{"trials":1190,"activeCount":77},[],{"trials":1192,"activeCount":77},[],{"trials":1194,"activeCount":77},[1195],{"nctId":438,"briefTitle":439,"status":117,"phases":1196,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":1197,"interventions":1198},[69],[15],[179,178,181,184,403,185,186,182,435,187,447,189,188,436,448,177,180,449],{"trials":1200,"activeCount":77},[],{"intervention":448,"totalTrials":73,"cells":1202},{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1207,"PHASE3":1209,"PHASE4":1211,"NA":1217},{"trials":1204,"activeCount":77},[],{"trials":1206,"activeCount":77},[],{"trials":1208,"activeCount":77},[],{"trials":1210,"activeCount":77},[],{"trials":1212,"activeCount":77},[1213],{"nctId":438,"briefTitle":439,"status":117,"phases":1214,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":1215,"interventions":1216},[69],[15],[179,178,181,184,403,185,186,182,435,187,447,189,188,436,448,177,180,449],{"trials":1218,"activeCount":77},[],{"intervention":175,"totalTrials":22,"cells":1220},{"EARLY_PHASE1":1221,"PHASE1":1223,"PHASE2":1225,"PHASE3":1236,"PHASE4":1242,"NA":1244},{"trials":1222,"activeCount":77},[],{"trials":1224,"activeCount":77},[],{"trials":1226,"activeCount":77},[1227],{"nctId":1228,"briefTitle":1229,"status":117,"phases":1230,"primaryCompletion":1231,"completion":1231,"start":454,"enrollment":1232,"conditions":1233,"interventions":1235},"NCT00684619","506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL)",[67],"2008-12",120,[1234],"T-ALL, T-NHL (Lymphoblastic)",[175],{"trials":1237,"activeCount":77},[1238],{"nctId":165,"briefTitle":166,"status":117,"phases":1239,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":1240,"interventions":1241},[68],[18,172],[174,175,176,63,177,178,179,180,181,182,183,184,185,186,187,188,189],{"trials":1243,"activeCount":77},[],{"trials":1245,"activeCount":77},[],{"intervention":176,"totalTrials":73,"cells":1247},{"EARLY_PHASE1":1248,"PHASE1":1250,"PHASE2":1252,"PHASE3":1254,"PHASE4":1260,"NA":1262},{"trials":1249,"activeCount":77},[],{"trials":1251,"activeCount":77},[],{"trials":1253,"activeCount":77},[],{"trials":1255,"activeCount":77},[1256],{"nctId":165,"briefTitle":166,"status":117,"phases":1257,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":1258,"interventions":1259},[68],[18,172],[174,175,176,63,177,178,179,180,181,182,183,184,185,186,187,188,189],{"trials":1261,"activeCount":77},[],{"trials":1263,"activeCount":77},[],{"intervention":627,"totalTrials":73,"cells":1265},{"EARLY_PHASE1":1266,"PHASE1":1268,"PHASE2":1270,"PHASE3":1272,"PHASE4":1278,"NA":1280},{"trials":1267,"activeCount":77},[],{"trials":1269,"activeCount":77},[],{"trials":1271,"activeCount":77},[],{"trials":1273,"activeCount":77},[1274],{"nctId":619,"briefTitle":620,"status":117,"phases":1275,"primaryCompletion":622,"completion":622,"start":623,"enrollment":624,"conditions":1276,"interventions":1277},[67,68],[15],[627,178],{"trials":1279,"activeCount":77},[],{"trials":1281,"activeCount":77},[],{"intervention":1283,"totalTrials":73,"cells":1284},"Allopurinol",{"EARLY_PHASE1":1285,"PHASE1":1287,"PHASE2":1289,"PHASE3":1291,"PHASE4":1304,"NA":1306},{"trials":1286,"activeCount":77},[],{"trials":1288,"activeCount":77},[],{"trials":1290,"activeCount":77},[],{"trials":1292,"activeCount":77},[1293],{"nctId":1294,"briefTitle":1295,"status":117,"phases":1296,"primaryCompletion":1297,"completion":1297,"start":1298,"enrollment":1299,"conditions":1300,"interventions":1302},"NCT00199043","Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma",[68],"2008-05","2003-05",80,[15,1301],"High-grade Lymphoma",[1283,1303],"Rasburicase",{"trials":1305,"activeCount":77},[],{"trials":1307,"activeCount":77},[],{"intervention":1303,"totalTrials":73,"cells":1309},{"EARLY_PHASE1":1310,"PHASE1":1312,"PHASE2":1314,"PHASE3":1316,"PHASE4":1322,"NA":1324},{"trials":1311,"activeCount":77},[],{"trials":1313,"activeCount":77},[],{"trials":1315,"activeCount":77},[],{"trials":1317,"activeCount":77},[1318],{"nctId":1294,"briefTitle":1295,"status":117,"phases":1319,"primaryCompletion":1297,"completion":1297,"start":1298,"enrollment":1299,"conditions":1320,"interventions":1321},[68],[15,1301],[1283,1303],{"trials":1323,"activeCount":77},[],{"trials":1325,"activeCount":77},[],{"intervention":1327,"totalTrials":73,"cells":1328},"Panobinostat",{"EARLY_PHASE1":1329,"PHASE1":1331,"PHASE2":1333,"PHASE3":1335,"PHASE4":1348,"NA":1350},{"trials":1330,"activeCount":77},[],{"trials":1332,"activeCount":77},[],{"trials":1334,"activeCount":77},[],{"trials":1336,"activeCount":77},[1337],{"nctId":1338,"briefTitle":1339,"status":1340,"phases":1341,"primaryCompletion":1342,"completion":1342,"start":1343,"enrollment":121,"conditions":1344,"interventions":1347},"NCT04326764","Panobinostat Maintenance After HSCT fo High-risk AML and MDS","TERMINATED",[68],"2023-02-13","2018-07-24",[1345,1346],"Acute Myeloid Leukaemia (AML)","Myelodysplastic Syndromes (MDS)",[1327],{"trials":1349,"activeCount":77},[],{"trials":1351,"activeCount":77},[],{"intervention":1353,"totalTrials":73,"cells":1354},"sodium chloride solution 0.9%",{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1359,"PHASE3":1372,"PHASE4":1374,"NA":1376},{"trials":1356,"activeCount":77},[],{"trials":1358,"activeCount":77},[],{"trials":1360,"activeCount":77},[1361],{"nctId":1362,"briefTitle":1363,"status":117,"phases":1364,"primaryCompletion":1365,"completion":1365,"start":1366,"enrollment":1367,"conditions":1368,"interventions":1370},"NCT01611116","Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia",[67],"2017-04-26","2012-05",33,[1369],"Acute Myeloblastic Leukemia",[1353,1371],"temsirolimus",{"trials":1373,"activeCount":77},[],{"trials":1375,"activeCount":77},[],{"trials":1377,"activeCount":77},[],{"intervention":1371,"totalTrials":73,"cells":1379},{"EARLY_PHASE1":1380,"PHASE1":1382,"PHASE2":1384,"PHASE3":1390,"PHASE4":1392,"NA":1394},{"trials":1381,"activeCount":77},[],{"trials":1383,"activeCount":77},[],{"trials":1385,"activeCount":77},[1386],{"nctId":1362,"briefTitle":1363,"status":117,"phases":1387,"primaryCompletion":1365,"completion":1365,"start":1366,"enrollment":1367,"conditions":1388,"interventions":1389},[67],[1369],[1353,1371],{"trials":1391,"activeCount":77},[],{"trials":1393,"activeCount":77},[],{"trials":1395,"activeCount":77},[],{"intervention":966,"totalTrials":73,"cells":1397},{"EARLY_PHASE1":1398,"PHASE1":1400,"PHASE2":1402,"PHASE3":1408,"PHASE4":1410,"NA":1412},{"trials":1399,"activeCount":77},[],{"trials":1401,"activeCount":77},[],{"trials":1403,"activeCount":77},[1404],{"nctId":957,"briefTitle":958,"status":117,"phases":1405,"primaryCompletion":960,"completion":960,"start":961,"enrollment":962,"conditions":1406,"interventions":1407},[67],[964],[966,406,967,968],{"trials":1409,"activeCount":77},[],{"trials":1411,"activeCount":77},[],{"trials":1413,"activeCount":77},[],{"intervention":967,"totalTrials":73,"cells":1415},{"EARLY_PHASE1":1416,"PHASE1":1418,"PHASE2":1420,"PHASE3":1426,"PHASE4":1428,"NA":1430},{"trials":1417,"activeCount":77},[],{"trials":1419,"activeCount":77},[],{"trials":1421,"activeCount":77},[1422],{"nctId":957,"briefTitle":958,"status":117,"phases":1423,"primaryCompletion":960,"completion":960,"start":961,"enrollment":962,"conditions":1424,"interventions":1425},[67],[964],[966,406,967,968],{"trials":1427,"activeCount":77},[],{"trials":1429,"activeCount":77},[],{"trials":1431,"activeCount":77},[],{"intervention":968,"totalTrials":73,"cells":1433},{"EARLY_PHASE1":1434,"PHASE1":1436,"PHASE2":1438,"PHASE3":1444,"PHASE4":1446,"NA":1448},{"trials":1435,"activeCount":77},[],{"trials":1437,"activeCount":77},[],{"trials":1439,"activeCount":77},[1440],{"nctId":957,"briefTitle":958,"status":117,"phases":1441,"primaryCompletion":960,"completion":960,"start":961,"enrollment":962,"conditions":1442,"interventions":1443},[67],[964],[966,406,967,968],{"trials":1445,"activeCount":77},[],{"trials":1447,"activeCount":77},[],{"trials":1449,"activeCount":77},[],{"intervention":1451,"totalTrials":73,"cells":1452},"Nilotinib",{"EARLY_PHASE1":1453,"PHASE1":1455,"PHASE2":1457,"PHASE3":1469,"PHASE4":1471,"NA":1473},{"trials":1454,"activeCount":77},[],{"trials":1456,"activeCount":77},[],{"trials":1458,"activeCount":77},[1459],{"nctId":1460,"briefTitle":1461,"status":117,"phases":1462,"primaryCompletion":1463,"completion":1463,"start":1464,"enrollment":1465,"conditions":1466,"interventions":1468},"NCT01528085","Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",[67],"2020-03-10","2012-01",79,[1467],"Philadelphia Chromsome Positive Acute Lymphoblastic Leukemia",[1451],{"trials":1470,"activeCount":77},[],{"trials":1472,"activeCount":77},[],{"trials":1474,"activeCount":77},[],{"intervention":1476,"totalTrials":73,"cells":1477},"BMC2012",{"EARLY_PHASE1":1478,"PHASE1":1480,"PHASE2":1482,"PHASE3":1493,"PHASE4":1495,"NA":1497},{"trials":1479,"activeCount":77},[],{"trials":1481,"activeCount":77},[],{"trials":1483,"activeCount":77},[1484],{"nctId":1485,"briefTitle":1486,"status":117,"phases":1487,"primaryCompletion":1488,"completion":1488,"start":1489,"enrollment":1490,"conditions":1491,"interventions":1492},"NCT02803177","Cell Therapy by Autologous BMC for Large Bone Defect Repair",[67],"2019-12-31","2016-07-02",55,[21],[1476],{"trials":1494,"activeCount":77},[],{"trials":1496,"activeCount":77},[],{"trials":1498,"activeCount":77},[],{"intervention":1020,"totalTrials":73,"cells":1500},{"EARLY_PHASE1":1501,"PHASE1":1503,"PHASE2":1505,"PHASE3":1511,"PHASE4":1513,"NA":1515},{"trials":1502,"activeCount":77},[],{"trials":1504,"activeCount":77},[],{"trials":1506,"activeCount":77},[1507],{"nctId":1010,"briefTitle":1011,"status":117,"phases":1508,"primaryCompletion":1013,"completion":1013,"start":1014,"enrollment":1015,"conditions":1509,"interventions":1510},[67],[1017,1018],[1020,449],{"trials":1512,"activeCount":77},[],{"trials":1514,"activeCount":77},[],{"trials":1516,"activeCount":77},[],{"intervention":1518,"totalTrials":73,"cells":1519},"Dasatinib",{"EARLY_PHASE1":1520,"PHASE1":1522,"PHASE2":1524,"PHASE3":1535,"PHASE4":1537,"NA":1539},{"trials":1521,"activeCount":77},[],{"trials":1523,"activeCount":77},[],{"trials":1525,"activeCount":77},[1526],{"nctId":1527,"briefTitle":1528,"status":117,"phases":1529,"primaryCompletion":1530,"completion":1530,"start":1531,"enrollment":8,"conditions":1532,"interventions":1534},"NCT01724879","Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)",[67],"2015-09","2011-11",[1533],"Philadelphia Positive Acute Lymphoblastic Leukemia",[1518],{"trials":1536,"activeCount":77},[],{"trials":1538,"activeCount":77},[],{"trials":1540,"activeCount":77},[],{"intervention":1542,"totalTrials":73,"cells":1543},"Ipilimumab plus nivolumab",{"EARLY_PHASE1":1544,"PHASE1":1546,"PHASE2":1548,"PHASE3":1561,"PHASE4":1563,"NA":1565},{"trials":1545,"activeCount":77},[],{"trials":1547,"activeCount":77},[],{"trials":1549,"activeCount":77},[1550],{"nctId":1551,"briefTitle":1552,"status":117,"phases":1553,"primaryCompletion":1554,"completion":1554,"start":1555,"enrollment":1556,"conditions":1557,"interventions":1559},"NCT03075423","Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC",[67],"2023-11-23","2017-11-01",316,[1558],"Metastatic Renal Cell Carcinoma",[1542,1560],"Standard Therapy",{"trials":1562,"activeCount":77},[],{"trials":1564,"activeCount":77},[],{"trials":1566,"activeCount":77},[],{"intervention":1560,"totalTrials":73,"cells":1568},{"EARLY_PHASE1":1569,"PHASE1":1571,"PHASE2":1573,"PHASE3":1579,"PHASE4":1581,"NA":1583},{"trials":1570,"activeCount":77},[],{"trials":1572,"activeCount":77},[],{"trials":1574,"activeCount":77},[1575],{"nctId":1551,"briefTitle":1552,"status":117,"phases":1576,"primaryCompletion":1554,"completion":1554,"start":1555,"enrollment":1556,"conditions":1577,"interventions":1578},[67],[1558],[1542,1560],{"trials":1580,"activeCount":77},[],{"trials":1582,"activeCount":77},[],{"trials":1584,"activeCount":77},[],{"intervention":1586,"totalTrials":73,"cells":1587},"Kineret 100 MG in 0.67 ML Prefilled Syringe",{"EARLY_PHASE1":1588,"PHASE1":1590,"PHASE2":1602,"PHASE3":1604,"PHASE4":1606,"NA":1608},{"trials":1589,"activeCount":77},[],{"trials":1591,"activeCount":77},[1592],{"nctId":1593,"briefTitle":1594,"status":117,"phases":1595,"primaryCompletion":1596,"completion":1596,"start":1597,"enrollment":11,"conditions":1598,"interventions":1600},"NCT04942626","Capecitabine-based Chemoradiotherapy in Combination With the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients",[66],"2024-12-31","2021-08-20",[1599],"Rectal Cancer",[1586,1601],"Capecitabine",{"trials":1603,"activeCount":77},[],{"trials":1605,"activeCount":77},[],{"trials":1607,"activeCount":77},[],{"trials":1609,"activeCount":77},[],{"intervention":1601,"totalTrials":73,"cells":1611},{"EARLY_PHASE1":1612,"PHASE1":1614,"PHASE2":1620,"PHASE3":1622,"PHASE4":1624,"NA":1626},{"trials":1613,"activeCount":77},[],{"trials":1615,"activeCount":77},[1616],{"nctId":1593,"briefTitle":1594,"status":117,"phases":1617,"primaryCompletion":1596,"completion":1596,"start":1597,"enrollment":11,"conditions":1618,"interventions":1619},[66],[1599],[1586,1601],{"trials":1621,"activeCount":77},[],{"trials":1623,"activeCount":77},[],{"trials":1625,"activeCount":77},[],{"trials":1627,"activeCount":77},[],{"intervention":1629,"totalTrials":73,"cells":1630},"BEZ235",{"EARLY_PHASE1":1631,"PHASE1":1633,"PHASE2":1647,"PHASE3":1649,"PHASE4":1651,"NA":1653},{"trials":1632,"activeCount":77},[],{"trials":1634,"activeCount":77},[1635],{"nctId":1636,"briefTitle":1637,"status":117,"phases":1638,"primaryCompletion":1639,"completion":1640,"start":1641,"enrollment":1642,"conditions":1643,"interventions":1646},"NCT01756118","A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia",[66],"2017-12","2020-02-07","2012-06",24,[18,1644,1645],"Leukemia, Myelocytic, Acute","Chronic Myelogenous Leukemia With Crisis of Blast Cells",[1629],{"trials":1648,"activeCount":77},[],{"trials":1650,"activeCount":77},[],{"trials":1652,"activeCount":77},[],{"trials":1654,"activeCount":77},[]]